Good move, obviously to also have a European strategy for drug development. Provides at least some backup to whatever goes on at FDA and hopefully opens a parallel path for treatment of conditions other than those first targeted in US.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.